Form 4: Guardant Health Grants 17,040 RSUs to Chief People Officer

Guardant Health, Inc. has granted 17,040 restricted stock units to Chief People Officer Terilyn J. Monroe, vesting over three years.

Summary

• Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc. (GH), was granted 17,040 Restricted Stock Units (RSUs).
• The transaction date for this grant was March 11, 2026.
• The RSUs have a vesting schedule over a three-year period.
• 33% of the shares subject to the award will vest on April 1, 2027.
• The remaining 67% of the shares will vest in equal quarterly installments over the subsequent two-year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive, routine event. It reflects standard executive compensation practices designed to align management incentives with long-term company performance, without indicating any extraordinary operational or financial developments.

Positives

• The grant of Restricted Stock Units aligns the Chief People Officer's interests with those of shareholders, incentivizing long-term performance.
• This form of equity compensation is a standard practice for retaining and motivating key executives.

Future Outlook

The vesting schedule for the Restricted Stock Units extends over a three-year period, indicating a long-term incentive structure for the Chief People Officer.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units, are a common and effective tool in the biotechnology and healthcare sectors for attracting, retaining, and motivating executive talent. This grant to Guardant Health's Chief People Officer is consistent with industry-standard compensation practices aimed at aligning executive incentives with shareholder value creation.

Comparison to Industry Standards

• The three-year vesting period for these RSUs is a common structure in the technology and healthcare industries, comparable to grants seen at companies like Illumina or Exact Sciences, which often use multi-year vesting schedules to promote long-term commitment and performance.
• The use of RSUs as a primary component of executive compensation is standard practice, similar to how companies such as Amgen or Gilead Sciences structure their executive incentive programs to tie compensation directly to company performance and stock appreciation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief People Officer's financial interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: This grant to a key executive may signal stability and a commitment to retaining top talent within the company.

Next Steps

• The Restricted Stock Units will vest according to the specified schedule, with the first tranche vesting on April 1, 2027, and subsequent quarterly installments over the following two years.

Key Dates

Keywords

Guardant Health, GH, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant